http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2021187087-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_07c9542186133097bd6bbb7d92393090
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-6056
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-60
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-555
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-6031
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-585
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-572
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55555
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55522
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-53
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-001106
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0011
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-001184
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-001193
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-001194
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00
filingDate 2021-03-03-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_718305bdfa0b7ac056096cbba112efab
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7be49b77bcb0a3b840c199c162fd5b4c
publicationDate 2021-06-24-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber US-2021187087-A1
titleOfInvention Targeting dna vaccines to b cells as primary antigen presenting cells
abstract It is disclosed herein that B cells, not dendritic cells or myeloid-derived populations, are primary human antigen presenting cells for plasmid DNA. Based on this finding, improved methods and compositions for administering DNA vaccines are disclosed. Specifically, DNA vaccines are co-administered with a B cell targeting agent, B-cell recruiting agent, or a monocyte or dendritic cell recruiting agent. To increase the immunogenicity of the DNA vaccines, the B cell targeting agent or B cell recruiting agent is administered at the same location where the DNA vaccine is administered. In contrast, the monocyte or dendritic cell recruiting agent can be administered in a different location, in order to recruit cells competing with the B cells for DNA uptake away from the location where the DNA vaccine is administered.
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11697851-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2020087625-A1
priorityDate 2014-11-07-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5283560
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395982
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395983
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5262

Total number of triples: 42.